These payloads block enzymes that support cancer-cell growth and stress responses. Antibody delivery is being studied as a way to direct those effects toward tumors.
The primary AACR abstract for HMPL-A580 describes an EGFR-directed antibody carrying a PI3K/PIKK inhibitor through a cleavable linker. Cell and xenograft experiments reported intracellular delivery, pathway inhibition and antitumor activity. PI3K and PIKK denote different kinase families; this broad payload label must not be reduced to a single selective kinase target without supporting data. The cited evidence is a preclinical conference abstract, not a clinical efficacy report.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/